Pharvaris (PHVS) Price & Analysis

Compare

123 Followers

PHVS Stock Chart & Stats

$21.59

-$0.46(-2.39%)

At close: Jan 08 4:00 PM EST

$21.59

-$0.46(-2.39%)

Day’s Range― - ―

52-Week Range$11.51 - $26.33

Previous CloseN/A

Volume14.65K

Average Volume (3M)226.40K

Market Cap

$1.38B

Enterprise ValueN/A

Total Cash (Recent Filing)$199.57M

Total Debt (Recent Filing)$634.15K

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Apr 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding64,055,640

10 Day Avg. Volume168,818

30 Day Avg. Volume226,397

Financial Highlights & Ratios

PEG Ratio1.31

Price to Book (P/B)3.73

Price to Sales (P/S)0.00

P/FCF Ratio-8.29

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$41.14

Price Target Upside90.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsRAPIDe-3 trial for on-demand HAE attack treatment is expected to deliver a significantly faster onset of relief vs placebo, paving the path to an approval.

Financial OutlookThe cash runway into 2027 supports late-stage execution and pre-commercial build, with a potential New Drug Application for on-demand deucrictibant.

Market PositionThe lead asset deucrictibant is the only oral bradykinin B2 receptor antagonist in development for both on-demand and prophylaxis settings, holding orphan drug designation in the U.S. and Europe.

Bears Say

CompetitionCompetitor KALV’s Ekterly has a head start as the only approved oral option for acute hereditary angioedema, which could limit the market opportunity for PHVS's drug.

Market ChallengesOral competitor BCRX’s Orladeyo, approved in 2020, has a significant head start in the prophylactic market, which could limit PHVS's usage to treatment failures.

Market ValuationThe current valuation assumes significant value for upcoming acute HAE data, but there is still a need for de-risking the prophylactic opportunity.

Pharvaris News

Six new option listings on October 24th

New option listings for October 24th include DeFi Development Corp (DFDV), Digi Power X Inc. (DGXX), Fg Nexus...

17d ago

SEV

DFDV

3 Best Stocks to Buy Now, 10/23/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

18d ago

AMZN

PHVS

Pharvaris initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Pharvaris (PHVS) with a Buy rating and $60 price target The company’s lead...

26d ago

PHVS

Promising Phase 3 Trial Data Drives Buy Rating for Deucrictibant

Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Pharvaris, retaining the price target of $43.00. Debanjana...

14d ago

PHVS

Pharvaris upgraded to Neutral from Underperform at BofA

BofA upgraded Pharvaris (PHVS) to Neutral from Underperform with a price target of $27, up from $16. Published...

1M ago

PHVS

BofA upgrades Pharvaris to Neutral on potential label expansion

As previously reported, BofA upgraded Pharvaris (PHVS) to Neutral from Underperform with a price target of $27, up...

1M ago

PHVS

Pharvaris Secures Registration Rights Agreement with General Atlantic

Pharvaris ( ($PHVS) ) just unveiled an update. On September 2, 2025, Pharvaris N.V. entered into a registration...

2M ago

PHVS

Pharvaris Advances Clinical Pipeline with Strong Financials

Pharvaris N.V. ( ($PHVS) ) has released its Q2 earnings. Here is a breakdown of the information Pharvaris...

3M ago

PHVS

Pharvaris’ Strategic Advancements and Financial Strength Bolster Buy Rating

Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Pharvaris, retaining the price target of $28.00....

3M ago

PHVS

Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on PHVS stock, giving a Buy rating today. Debanjana...

3M ago

PHVS

Pharvaris price target lowered to $52 from $55 at Citizens JMP

Citizens JMP lowered the firm’s price target on Pharvaris (PHVS) to $52 from $55 and keeps an Outperform...

3M ago

PHVS

Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies

Pharvaris ( ($PHVS) ) has shared an announcement. On August 12, 2025, Pharvaris reported its financial results for...

3M ago

PHVS

Pharvaris Raises $201 Million in Successful Offering

Pharvaris ( ($PHVS) ) has provided an announcement. On July 22, 2025, Pharvaris N.V. entered into an underwriting...

4M ago

PHVS

Pharvaris 8.25M share Spot Secondary priced at $20.00

he deal size was increased to $175M in common stock and warrants from $150M. Morgan Stanley, Leerink, Cantor...

4M ago

PHVS

PHVS FAQ

What was Pharvaris’s price range in the past 12 months?

Pharvaris lowest stock price was $11.51 and its highest was $26.33 in the past 12 months.

What is Pharvaris’s market cap?

Pharvaris’s market cap is $1.38B.

When is Pharvaris’s upcoming earnings report date?

Pharvaris’s upcoming earnings report date is Apr 14, 2026 which is in 155 days.

How were Pharvaris’s earnings last quarter?

Currently, no data Available

Is Pharvaris overvalued?

According to Wall Street analysts Pharvaris’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharvaris pay dividends?

Pharvaris does not currently pay dividends.

What is Pharvaris’s EPS estimate?

Pharvaris’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharvaris have?

Pharvaris has 64,055,640 shares outstanding.

What happened to Pharvaris’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pharvaris?

Currently, no hedge funds are holding shares in PHVS

Pharvaris Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.96%

Trailing 12-Months

Asset Growth

-34.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharvaris

Pharvaris (PHVS) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative oral therapies for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary small molecule chemistry platform to create novel treatments aimed at improving patient outcomes and quality of life.

Pharvaris (PHVS) Earnings & Revenues

Historic Earnings Reports

PHVS Stock 12 Month Forecast

Average Price Target

$41.14

▲(90.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","25":"$25","37":"$37","49":"$49","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,25,37,49,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.06,26.824615384615385,29.589230769230767,32.35384615384615,35.11846153846154,37.88307692307692,40.64769230769231,43.41230769230769,46.176923076923075,48.94153846153846,51.70615384615384,54.47076923076923,57.23538461538462,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.06,25.373846153846152,26.687692307692306,28.00153846153846,29.315384615384616,30.629230769230766,31.943076923076923,33.25692307692307,34.57076923076923,35.88461538461539,37.19846153846154,38.512307692307694,39.826153846153844,{"y":41.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.06,24.286153846153844,24.51230769230769,24.738461538461536,24.964615384615385,25.19076923076923,25.416923076923077,25.643076923076922,25.869230769230768,26.095384615384614,26.32153846153846,26.54769230769231,26.773846153846154,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >